
WELCOME!
Thank you for joining today's meeting. We will begin shortly.

Puerto Rico IDeA Network of Biomedical Research Excellence

Town Hall Meeting

April 16, 2021

Program Overview

Presented by

Jose R. Rodriguez Medina

PI/PD

PRINBRE

IDeA Network of Biomedical Research Excellence

Background

- INBRE has been active in Puerto Rico since **2001.**
- Currently in **Year 1** of a new cycle (July 15, 2021 to June 30, 2026.

Note: *Year 3 (Hurricane Maria & Irma) the reporting period changed



PRINBRE

IDeA Network of Biomedical Research Excellence

Program Officer-NIH

Principal Investigator

External Advisory Committee

Program Coordinator

Evaluation & Tracking

Administrative Core
Program Administrator
Administrative Assistant
Project Coordinator

Steering Committee

Mentoring Coordinator

Bioinformatics
Core Directors

Access to Biomedical Electronic Scientific Information

Data Visualization & Data Analysis

Centralized Research and Instrumentation
Core Director

Developmental Research Projects Program
Research Coordinator

Science, Technology, and Competency Enhancement
Core Director

Community Based Research

DNA Sequencing & Genotyping
Facility Coordinator

Genetics
Facility Coordinator

Proteomics
Facility Coordinator

Metabolomics
Facility Coordinator

ChemTox
Facility Coordinator

Protein Dynamics
Facility Coordinator

External Advisory Committee

James R. Brown M.Sc., Ph.D.
Senior Director
Computational Biology and Integrated
Data Science Kaleido Biosciences
Lexington MA 02421 USA

Reinhard Laubenbacher, Ph.D.
Dean's Professor of Systems Medicine
Director, Laboratory for Systems Medicine
Division of Pulmonary, Critical Care,
and Sleep Medicine
Department of Medicine
University of Florida

Sanjay V. Malhotra, Ph.D., FRSC
Professor & Endowed Chair in Cancer Research
Director, Center for Experimental Therapeutics
Oregon Health & Science University

Stephen J. Cutler, Ph.D.
Dean and Professor
College of Pharmacy
University of South Carolina

Veronica Martinez, Ph.D.
Associate Prof. in Residence
Pathology & Laboratory Medicine
University of California at Davis


EAC Members 2019



Dr. Robert M. Williams passed away on May 13, 2020






NETWORK IMPACT










PR-INBRE
Network institutions
UPR-MSC
UPR-Rio Piedras
UAGM Cupey
InterAmerican Univ.
Carlos Albizu Univ.
Univ Central Carbb.
InterAmerican Univ.-
Bayamon
UPR-Aguadilla
San Juan
UAGM Carolina
Bayamon
Carolina
Caguas
UPR-
Mayaguez
UAGM Gurabo
Cayey
UPR-Humacao
InterAmerican Univ.
San German
UPR-Cayey
Ponce
Ponce Sch. of Med.
UPR-Ponce
Pontifical Catholic Univ.
PUERTO RICO

Build on the established multi-disciplinary research network with a scientific focus to strengthen the lead and partner institutions' biomedical research expertise and infrastructure

Enhance the research capacity of network institutions so they can participate more fully in the competition for NIH awards

collaborative partnerships
development of areas of potential research
research support for faculty development
access to research resources



Provide hands-on research experiences, mentoring, and career development activities for students and faculty at primarily undergraduate institutions, community colleges, and minority serving institutions, and serve as a pipeline to health research careers

All Grants @t the PR-INBRE Network by years

Year	Submitted	Awarded	Amount Awarded
2015-2016	108	21	$3,767,107
2016-2017	169	85	$5,082,556
2017-2018	83	45	$12,900,368
2019	223	43	$29,080,255
2020-present	124	27	$9,081,229
Total	**707**	**221**	$59,911,515

Yr. 2019, PHSU awarded with U54 ($21M)

Grants include NIH, NSF, Department of Education, Other federal agencies, Foundations, State Funds

Data Source: Network Institutional Profile, NIH Reporter



Publications with PMCID by Years



98

Presentations

Yr. 2020-Present

Total Presentations by Years





DRPP Investigators

Grants Awarded by years



Grants Awarded may include R21, R15, SC1, NSF, FIPI, PRST, Foundations

STEM Students @t the Network

Pursued
12,843

Degrees Awarded
1,772

PRINBRE
IDeA Network of Biomedical Research Excellence

Data Source: Institutional Profile 2020, N=9

119

Students mentored
by **DRPP investigators**
Year 2020-Present

2015-2016	2016-2017	2017-2018	2019
68 students	**112** students	**153** students	**162** students

Development of STEM Curriculum at Network

18 **New courses** at PUIs and OI

Seminars & Workshops

24 activities

530 participants

96% average satisfaction

Calls for Junior Research Associates **applications**, Faculty **Travel** Awards, Support for Access to **Scientific Articles**, and other programs will be issued.



Call for Abstracts

The Puerto Rico IDeA Programs are honored to host a three-day meeting of talks, activities, and workshops. The Regional Conference has served as an important platform to discuss matters of science, administrative policy, and best practices in a cordial and interactive scholarly environment.

Abstract Submission Deadline:
September 15, 2021

Conference Information and registration:
https://www.seidea21.hpcf.upr.edu

The Alliance · PRINBRE IDeA Network of Biomedical Research Excellence · COBRE Center for Neuroplasticity at the University of Puerto Rico · UPR Recinto de Ciencias Medicas

Follow the PR-INBRE Website for updates

http://inbre.hpcf.upr.edu/


Like us on
facebook
LinkedIn



Puerto Rico IDeA Network Biomedical Research Excellence

PRINBRE

Informational Workshop Developmental Research Projects Program 2021-2023 Grant Cycle

Su Dharmawardhane, Ph.D.
INBRE DRPP Director
758-2525X1623
Su.d@upr.edu

inbre_proposals@hpcf.upr.edu

NIH/NIGMS P20GM103475-19

Our mission: To increase and develop the talent pool in PR

Puerto Rico IDeA Network Biomedical Research Excellence

PRINBRE

OUTLINE

1. PR-INBRE Developmental Research Projects Program (DRPP) Funding process overview
2. PHS 398 Forms- what we expect
3. Composition of an Abstract/Summary
4. Specific Aims Page
5. Approach section
6. Additional attachments

Core Goals and Aims

Provide mentoring and financial support to the developmental project investigators in **four** scientific cluster areas:

1. **Neuroscience**
2. **Molecular Medicine/ Genomics**
3. **Drug Discovery and Development**
4. **Bioinformatics**

- Support meritorious research to give release time and enable generation of data to submit manuscripts and grant proposals!
- Success is measured by independent awards from NIH, NSF, DoD, etc.

2P20GM103475-19

INBRE budget: 1.5 million

07.15.2021-07.14.2022

Aim 1: Full project funding ($100,000/yr) for 2.5 years ($250,000)

Aim 2: Pilot projects $50,000/yr

Aim 3:

- Small instrumentation grants $25,000 each
- Feasibility grants $10,000 each

Specific Aim 3: Enhance the research infrastructure of the PUIs and reinforce access to core facilities.

Aim 3A. Small instrumentation grants for PUIs.

- $25,000 each non-renewable for small instrument needs

Aim 3B. Mini grants for feasibility studies.

- ~$5-10,000 each, nonrenewable for collaborative projects-grant or manuscript submission
  to **use the INBRE core facilities.**

PR-INBRE


Not Eligible for funding under DRPP
Eligible for Pilot Projects
Eligible for both Full and Pilot Projects
University of Puerto Rico (UPR) Medical Sciences Campus
UPR-Rio Piedras Campus
10 ORIs:
Ponce School of Health Sciences
Univ. Central del Caribe
UPR-Aguadilla
UPR-Ponce
UPR-Carolina
Pontifical Catolica Univ.
Interamericana Bayamón
Interamericana San German
Sagrado Corazon Univ.
Carlos Albizu Univ.
7 PUIs:
UPR-Mayaguez
UPR-Cayey
UPR-Humacao
UAGM Gurabo
UAGM Carolina
UAGM Cupey
InterAmerican Metropolitan

PR-INBRE DRPP Funding Cycle 6



PRINBRE
IDeA Network of Biomedical Research Excellence

What happens to your application?

Applications due Oct 07, 2021
Inbre_proposals@hpcf.upr.edu

October 2nd Week: First Tier Review
1 Reviewer INBRE Administrative core
1 Reviewer in PR
1-2 Reviewers outside of PR

Nov-Dec 2021: Internal Review Committee:
Second Tier Review
Full≤30, Pilot≤35
Technical merit, **S**cientific excellence, and **P**rogrammatic relevance.

Third Tier Review
External Advisory Committee

Final Approval from NIH Program Office for Compliance
January 2021

Overall Impact:

The likelihood that a project will have a sustained and powerful influence on science (and/or clinical practice and/or technological developments?)

Overall Impact	High	Medium	Low
Score	1 2 3	4 5 6	7 8 9

Evaluating Overall Impact:

Consider the 5 criteria: significance, investigator, innovation, approach, environment (weighted based on reviewer's judgment)

e.g. Applications are addressing a problem of high importance in the field. May have some or no weaknesses.

e.g. Applications may be addressing a problem of high importance in the field, but weaknesses in the criteria bring down the overall impact to medium.

e.g. Applications may be addressing a problem of moderate importance in the field, with some or no weaknesses

e.g. Applications may be addressing a problem of moderate/high importance in the field, but weaknesses in the criteria bring down the overall impact to low.

e.g. Applications may be addressing a problem of low or no importance in the field, with some or no weaknesses.

NIH Center for Scientific Review

5 is a good medium-impact application, and the entire scale (1-9) should always be considered.

Each Reviewer will assign a score using the following criteria:

1. **Significance**
2. **Investigators**
3. **Innovation**
4. **Approach**

Non Scored Criteria: Environment, Protection of human subjects

Puerto Rico IDeA Network Biomedical Research Excellence

PRINBRE

Funding Opportunity Announcement (FOA)

- Please, use PHS398 forms (SF424 forms will not be accepted)!
- A developmental mentoring/collaboration plan is mandatory:

	Full Proposals	Pilot Proposals
Application page limit	12	6
Mentoring/Collaboration Plan	Should be included within the 12-page limit	Should be included within the 6-page limit
Required Support Letters	Letter or e-mail from the mentor and a letter of support from Department chair detailing full time employment as faculty with approval of at least 50% release time.	Letter or e-mail from the collaborator and a letter of support from Department chair detailing full time employment as faculty with approval of at least 25% release time.
IRB and IACUC Applications	Evidence required if applicable	Evidence required if applicable
Number of anticipated awards	1	10
Total Period Funding	$250,000	$75,000
Maximum Project period	2.0 yrs and 5 months	1 yr and 5 months

If the project involves OMICS or statistics- please consult with PRINBRE Bioinformatics core! http://inbre.hpcf.upr.edu/bioinformatics-resource-core/

Developmental Plan

Mandatory Training/Developmental Plan:

- Include a detailed training and Individual Development Plan (IDP). Identify weaknesses and indicate how collaborators and mentors can fill these gaps. Discuss how mentors and collaborators will specifically help the proposed research and your IDP.
- Indicate plans for training, conferences, publications, and grant applications.
- Explain how you would use this mechanism to leverage independent federal funding.

- The INBRE Leadership and the EAC can help you!

INBRE EAC Expertise

- EAC member Reinharad Laubenbenbacher, Ph.D., Professor, Jackson Laboratory Cancer Center
  https://www.jax.org/research-and-faculty/faculty/reinhard-laubenbacher
  Bioinformatics

- EAC Member Dr. James Brown, Director, Computational Biology & GlaxoSmithKline Senior Fellow
  https://www.linkedin.com/in/james-brown-1b652a6/
  drug development, Bioinformatics, and computational biology

- EAC Member Dr. Sanjay Malhotra, Professor, Ohio Health Sciences University
  https://www.ohsu.edu/school-of-medicine/malhotra-lab/people
  Experimental therapeutics for cancer

- EAC Member Dr. Stephen Cutler, Dean, College of Pharmacy, University of South Carolina
  https://www.sc.edu/study/colleges_schools/pharmacy/faculty-staff/cutler_stephen.php
  Natural products chemistry

- EAC Member Dr. Verónica Martinez-Cedeño, Professor, University of California, Davis.
  https://biology.ucdavis.edu/people/veronica-martinez-cerdeno
  Expertise in neuroscience, neurodegenerative diseases, autism

INBRE Cores
http://inbre.hpcf.upr.edu/

- **Bioinformatics Resources Core (BiRC)**: Director, Dr. Humberto Ortiz: For assistance with bioinformatics and statistical design visit http://inbre.hpcf.upr.edu/bioinformatics-resource-core/

- **Centralized Research Instrumentation (CRI):** (http://inbre.hpcf.upr.edu/centralized-research-instrumentation/)

  Genomics: Dra. Carmen Cadilla; **Sequencing and Genotyping**: Dr. Ricardo Pappas; **Proteomics**, Dra. Loyda Melendez; **Metabolomics**, Dra. Natalya Chorna, and **Chem Tox**, Dra. Beatriz Zayas

  Small Grants Program gives $5,000 to use INBRE core services!

- **Science and Technology Competency Enhancement Core (STCE):** Director, Dr. José Rodríguez-Orengo. Student stipends and student and faculty summer internships. http://inbre.hpcf.upr.edu/stce/

- **Developmental Research Projects Program (DRPP):** Drs. Su Dharmawardhane and Mariangeline Gonzalez has expertise in cancer biology, breast and pancreatic cancer, and cell and mouse models for testing experimental therapeutics

http://grants.nih.gov/grants/funding/phs398/phs398.html

Grant Application PHS 398 (Revised 03/2020)

Form Page 1: Face Page
Form Page 2: Summary, Relevance, Project/Performance Sites, Senior/Key Personnel (Biosketches 5 page), Other Significant Contributors, and Human Embryonic Stem Cells
Form Page 3: Research Grant Table of Contents
Form Page 4: Detailed Budget for Initial Budget Period
Form Page 5: Budget for Entire Proposed Project Period (Modular Budget Form, with budget justification)
Resources Format Page
Checklist Form
For Human subjects research:
Planned Enrollment Report
Cumulative Inclusion Enrollment Report

Form page 1

Form Approved Through 05/31/2020

OMB No. 0925-0001

Department of Health and Human Services
Public Health Services

Grant Application

Do not exceed character length restrictions indicated.

LEAVE BLANK—FOR PHS USE ONLY.

Type	Activity	Number
Review Group		Formerly
Council/Board (Month, Year)		Date Received

1. TITLE OF PROJECT *(Do not exceed 81 characters, including spaces and punctuation.)*

2. RESPONSE TO SPECIFIC REQUEST FOR APPLICATIONS OR PROGRAM ANNOUNCEMENT OR SOLICITATION ☐ NO ☐ YES
(If "Yes," state number and title)
Number: Title:

3. PROGRAM DIRECTOR/PRINCIPAL INVESTIGATOR

3a. NAME (Last, first, middle)	3b. DEGREE(S)	3h. eRA Commons User Name
3c. POSITION TITLE	3d. MAILING ADDRESS *(Street, city, state, zip code)*	
3e. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT		
3f. MAJOR SUBDIVISION		
3g. TELEPHONE AND FAX *(Area code, number and extension)* TEL: FAX:	E-MAIL ADDRESS:	

4. HUMAN SUBJECTS RESEARCH ☐ No ☐ Yes	4a. Research Exempt ☐ No ☐ Yes	If "Yes," Exemption No.
4b. Federal-Wide Assurance No.	4c. Clinical Trial ☐ No ☐ Yes	4d. NIH-defined Phase III Clinical Trial ☐ No ☐ Yes
5. VERTEBRATE ANIMALS ☐ No ☐ Yes	5a. Animal Welfare Assurance No.	

6. DATES OF PROPOSED PERIOD OF SUPPORT *(month, day, year—MM/DD/YY)*		7. COSTS REQUESTED FOR INITIAL BUDGET PERIOD		8. COSTS REQUESTED FOR PROPOSED PERIOD OF SUPPORT	
From	Through	7a. Direct Costs ($)	7b. Total Costs ($)	8a. Direct Costs ($)	8b. Total Costs ($)

9. APPLICANT ORGANIZATION Name Address	10. TYPE OF ORGANIZATION Public: → ☐ Federal ☐ State ☐ Local Private: → ☐ Private Nonprofit For-profit: → ☐ General ☐ Small Business ☐ Woman-owned ☐ Socially and Economically Disadvantaged 11. ENTITY IDENTIFICATION NUMBER DUNS NO. Cong. District

12. ADMINISTRATIVE OFFICIAL TO BE NOTIFIED IF AWARD IS MADE	13. OFFICIAL SIGNING FOR APPLICANT ORGANIZATION
Name Title Address Tel: FAX: E-Mail:	Name Title Address Tel: FAX: E-Mail:

14. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.	SIGNATURE OF OFFICIAL NAMED IN 13. *(In ink. "Per" signature not acceptable.)*	DATE

Title of Project: 81 characters
Must be the same as your LOI, approved IACUC or human IRB protocol. *The title should capture the essence of project objectives*

Human subjects and animal research: Yes or NO
If Yes: add correct Federal-wide assurance number for human subjects research
And animal welfare assurance No. for animal research

Dates of Proposal:
Initial: 02/01/22-06/30/22
Full=$50,000
Pilot=$25,000
Total:
Full: 02/02/22-06/30/24
=$50,000+200,000=$250,000
Pilot: 02/02/22-06/30/23
=$25,000+50,000=$75,000

Please include signature

Form Page 2

Program Director/Principal Investigator (Last, First, Middle):

PROJECT SUMMARY (See instructions):

Please, fill this space.
Do NOT give a separate attachment!

RELEVANCE (See instructions):

Why should NIH fund it?

PROJECT/PERFORMANCE SITE(S) (if additional space is needed, use Project/Performance Site Format Page)

Project/Performance Site Primary Location		
Organizational Name:		
DUNS:		
Street 1:	Street 2:	
City:	County:	State:
Province:	Country:	Zip/Postal Code:
Project/Performance Site Congressional Districts:		

Additional Project/Performance Site Location		
Organizational Name:		
DUNS:		
Street 1:	Street 2:	
City:	County:	State:
Province:	Country:	Zip/Postal Code:
Project/Performance Site Congressional Districts:		

Project Summary:
30 lines

Hypothesis-Driven Research

- Concise presentation of the project.
- Include the project's broad, long-term objectives and specific aims
- Include a description of the research design and methods for achieving the stated goals
- Write in plain language, so even a non-scientist can understand the importance of the project

What are you going to do, why you are doing it, what do you hope to find?

Project Relevance:
Maximum 3 sentences on the biomedical relevance of the project.

Code Words in Project Summary

LONG TERM GOAL/S
CRITICAL NEED
GAP IN KNOWLEDGE
OBJECTIVE
RATIONALE
CENTRAL HYPOTHESIS
SPECIFIC AIMS
IMPACT

RELEVANCE:
3 sentences on health relevance

NIH-Wide Strategic Plan

Fiscal Years 2016-2020

PROJECT NARRATIVE

Genetically similar viruses can cause widely disparate diseases through manipulation of innate immune pathways. This project uses mammalian reovirus, a powerful experimental model for studies of virus pathogenesis, to identify mechanisms for strain-specific differences in cellular responses to infection that influence organ-specific disease. As other pathogenic microbes employ similar strategies, this research program will uncover conserved mechanisms of infectious disease pathogenesis.

Table of Contents

Program Director/Principal Investigator (Last, First, Middle):

The name of the program director/principal investigator must be provided at the top of each printed page and each continuation page.

RESEARCH GRANT

TABLE OF CONTENTS

* Follow the page limits for these sections indicated in the application instructions, unless the Funding Opportunity Announcement specifies otherwise.

Please, note that the **Bibliography (References)** are included after the Research Strategy and is not constrained by page limits.

Whose doing the study?

Program Director/Principal Investigator (Last, First, Middle):

SENIOR/KEY PERSONNEL. See instructions. *Use continuation pages as needed* to provide the required information in the format shown below. Start with Program Director(s)/Principal Investigator(s). List all other senior/key personnel in alphabetical order, last name first.

Name	eRA Commons User Name	Organization	Role on Project

OTHER SIGNIFICANT CONTRIBUTORS

Name	Organization	Role on Project

Human Embryonic Stem Cells ☐ **No** ☐ **Yes**

If the proposed project involves human embryonic stem cells, list below the registration number of the specific cell line(s) from the following list: https://grants.nih.gov/stem_cells/registry/current.htm. *Use continuation pages as needed.*

If a specific line cannot be referenced at this time, include a statement that one from the Registry will be used.

Cell Line

Chose Wisely…..

Include NIH Biosketches

Key personnel: Ph.D./MD
PI
Mentor
Collaborator
Post Doc

Biographical Sketch

OMB No. 0925-0001 and 0925-0002 (Approved Through 02/28/2023)
BIOGRAPHICAL SKETCH INSTRUCTIONS

https://grants.nih.gov/grants/forms/biosketch.htm

NOTE: The Biographical Sketch may not exceed five pages.

Fill in the name of the senior/key person or other significant contributor in the "Name" field of the Biosketch Format Page.

eRA Commons User Name:
If the individual is registered in the eRA Commons, fill in the eRA Commons User Name in the "eRA Commons User Name" field of the Biosketch Format Page.

Position Title:
Fill in the position title of the senior/key person or other significant contributor in the "Position Title" field of the Biosketch Format Page.

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Hunt, Morgan Casey

eRA COMMONS USER NAME (credential, e.g., agency login): huntmc1

POSITION TITLE: Associate Professor of Psychology

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY
University of California, Berkeley	BS	05/2003	Psychology
University of Vermont	PHD	05/2009	Experimental Psychology
University of California, Berkeley	Postdoctoral	08/2013	Public Health and Epidemiology

A. Personal Statement

I am an Associate Professor of Psychology, and my research is focused on neuropsychological changes associated with substance use disorders. I have a broad background in psychology, with specific training and expertise in ethnographic and survey research and secondary data analysis on psychological aspects of substance use disorders. As PI or co-Investigator on several university- and NIH-funded grants, I laid the groundwork for the proposed research by developing effective measures of disability, depression, and other psychosocial factors relevant to older people with substance use disorders, and by establishing strong ties with community providers that will make it possible to recruit and track participants over time as documented in the following publications. In addition, I successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project. As a result of these previous experiences, I am aware of the importance of frequent communication among project members and of constructing a realistic research plan, timeline, and budget. The current application builds logically on my prior work. During 2015-2016, my career was disrupted due to family obligations. However, upon returning to the field, I immediately resumed my research projects and collaborations and successfully competed for NIH support. In summary, I have the expertise, leadership, training, expertise, and motivation necessary to successfully carry out the proposed research project.

Ongoing and recently completed projects that I would like to highlight include:

R01 DA942367
Hunt (PI)
09/01/16-08/31/21
Health trajectories and behavioral interventions among older people with substance use disorders

R01 MH922731
Merryle (PI), Role: co-investigator
12/15/17-11/30/22
Physical disability, depression, and substance use among older adults

A. Personal Statement

Briefly describe why you are well-suited for your role(s) in this project. Relevant factors: aspects of your training; your previous experimental work on this specific topic or related topics; your technical expertise; your collaborators or scientific environment; and/or your past performance in this or related fields, including ongoing and completed research projects from the past three years that you want to draw attention to (previously captured under Section D. Research Support).

Citations:

1. Merryle, R.J. & **Hunt, M.C.** (2015). Independent living, physical disability and substance use among older adults. Psychology and Aging, 23(4), 10-22.
2. **Hunt, M.C.**, Jensen, J.L. & Crenshaw, W. (2018). Substance use and mental health among community-dwelling older adults. International Journal of Geriatric Psychiatry, 24(9), 1124-1135.
3. **Hunt, M.C.**, Wiechelt, S.A. & Merryle, R. (2019). Predicting the substance use treatment needs of an aging population. American Journal of Public Health, 45(2), 236-245. PMCID: PMC9162292
4. Merryle, R. & **Hunt, M.C.** (2020). Randomized clinical trial of cotinine in older people with nicotine use disorder. Age and Aging, 38(2), 9-23. PMCID: PMC9002364

B. Positions, Scientific Appointments, and Honors

Positions and Scientific Appointments

2021– Present	Associate Professor, Department of Psychology, Washington University, St. Louis, MO
2020 – Present	Adjunct Professor, McGill University Department of Psychology, Montreal, Quebec, Canada
2018 – Present	NIH Risk, Adult Substance Use Disorder Study Section, member
2015 – 2017	Consultant, Coastal Psychological Services, San Francisco, CA
2014 – 2021	Assistant Professor, Department of Psychology, Washington University, St. Louis, MO
2014 – 2015	NIH Peer Review Committee: Psychobiology of Aging, ad hoc reviewer
2014 – Present	Board of Advisors, Senior Services of Eastern Missouri
2013 – 2014	Lecturer, Department of Psychology, Middlebury College, Middlebury, VT
2011 – Present	Associate Editor, Psychology and Aging
2009 – Present	Member, American Geriatrics Society
2009 – Present	Member, Gerontological Society of America
2009 – 2013	Fellow, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD
2006 – Present	Member, American Psychological Association

Honors

2020	Award for Best in Interdisciplinary Ethnography, International Ethnographic Society
2019	Excellence in Teaching, Washington University, St. Louis, MO
2018	Outstanding Young Faculty Award, Washington University, St. Louis, MO

You may cite up to four publications or research products that highlight your experience and qualifications for this project: audio or video products; conference proceedings such as meeting abstracts, posters, or other presentations;
Patents;
data and research materials;
Databases;
educational aids or curricula;
instruments or equipment;
models; protocols;
and software or netware.
Use of hyperlinks and URLs to cite these items is not allowed.
You are allowed to cite **interim research products:**
e.g. preprints of accepted articles, pre-registered protocols

B. List in **reverse chronological order all current positions** and scientific appointments both domestic and foreign, including affiliations with foreign entities or governments. This includes titled academic, professional, or institutional appointments whether or not remuneration is received, and whether full-time, part-time, or voluntary (including adjunct, visiting, or honorary).

List any relevant academic and professional achievements and **honors**. Students, postdocs, and junior faculty should include scholarships, traineeships, fellowships, and development awards.
Clinicians should include information on any clinical licensures and specialty board certifications that they have achieved.

C. Contribution to Science

Format: Briefly describe **up to five** of your most significant contributions to science. The description of each contribution should be no longer than one half page, including citations.

Content: *Figures, tables, or graphics are not allowed.*

For each contribution, indicate the following:

- the historical background that frames the scientific problem;
- the central finding(s);
- the influence of the finding(s) on the progress of science or the application of those finding(s) to health or technology;
- your specific role in the described work.

For each contribution, you may cite up to **four publications** or research products that are relevant to the contribution. If you are not the author of the product, indicate what your role or contribution was. Note that while you may mention manuscripts that have not yet been accepted for publication as part of your contribution, **you may cite only published papers to support each contribution.**

You may provide a URL to a full list of your published work. This URL must be to a Federal Government website (a .gov suffix). NIH recommends using My Bibliography. Providing a URL to a list of published work is not required.

D. Additional Information: *Research Support changed to Scholastic Performance*

Other Support

https://grants.nih.gov/grants/forms/othersupport.htm
Due dates on/before January 24, 2022

OMB No. 0925-0001 (Rev. 03/2020 Approved Through 02/28/2023)

For New and Renewal Applications – DO NOT SUBMIT UNLESS REQUESTED

PHS 398 OTHER SUPPORT

Provide active and pending support for all senior/key personnel. **Other Support includes all financial resources, whether federal, non-federal, commercial or institutional, available in direct support of an individual's research endeavors, including but not limited to research grants, cooperative agreements, contracts, and/or institutional awards.** Training awards, prizes, or gifts do not need to be included.

There is no "form page" for reporting Other Support. Information on Other Support should be provided in the *format* shown below.

For information pertaining to the use of and policy for other support, see NIH Grants Policy Statement, Section 2.5.1: Just-in-Time Procedures. Neither the application under consideration nor the current PHS award for this project should be listed as Other Support.

Effort devoted to projects must be measured using "person months." NIH and other PHS agencies use the concept of "person months" as a metric for determining percent of effort. For more information about calculating person months, see NIH's Frequently Asked Questions on Person Months.

Format

NAME OF INDIVIDUAL ACTIVE/PENDING		
Project Number (Contact Principal Investigator) Source Title of Project *(or Subproject)* The major goals of this project are…	Dates of Approved/Proposed Project Annual Direct Costs	Person Months (Cal/Academic/ Summer)
OVERLAP *(summarized for each individual)*		

OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)

Due dates on/after January 25, 2022

For New and Renewal Applications – DO NOT SUBMIT UNLESS REQUESTED
PHS 398 OTHER SUPPORT

There is no "form page" for reporting Other Support. Information on Oth
provided in the format shown below.

*Name of Individual:
Commons ID:

Other Support – Project/Proposal

*Title:

Major Goals:

*Status of Support:

Project Number:

Name of PD/PI:

*Source of Support:

*Primary Place of Performance:

Project/Proposal Start and End Date: (MM/YYYY) (if available):

* Total Award Amount (including Indirect Costs):

* Person Months (Calendar/Academic/Summer) per budget period.

Year (YYYY)	Person Months (##.##)
1. [enter year 1]	
2. [enter year 2]	
3. [enter year 3]	
4. [enter year 4]	
5. [enter year 5]	

Other support includes all resources made available to researchers or senior key personnel in support of and/or related to all of their research endeavors, regardless of whether or not they have monetary value and regardless of whether they are based at the institution the researcher identifies for the current grant.

This includes: resources and/or financial support from all foreign and domestic entities that are available to the researcher. This includes, but is not limited to, financial support for laboratory personnel, and provision of high-value materials that are not freely available (e.g., biologics, chemicals, model systems, technology, etc.). Institutional resources, such as core facilities or shared equipment that are made broadly available, should not be included in Other Support, but rather listed under Facilities and Other Resources.

OMB No. 0925-0001 and 0925-0002 (Rev. 12/2020 Approved Through 02/28/2023)

Name of Individual:
Commons ID:

IN-KIND

*Summary of In-Kind Contribution:

*Status of Support:

*Primary Place of Performance:

Project/Proposal Start and End Date (MM/YYYY) (if available):

*Person Months (Calendar/Academic/Summer) per budget period

Year (YYYY)	Person Months (##.##)
1. [enter year 1]	
2. [enter year 2]	
3. [enter year 3]	
4. [enter year 4]	
5. [enter year 5]	

*Estimated Dollar Value of In-Kind Information:

***Overlap** (summarized for each individual):

If in-kind contributions **are intended for use on the project being proposed** to NIH in this application, the information must be included as part of the Facilities and Other Resources or Equipment section of the application and need not be replicated on this form.
In-kind contributions **not intended for use on the project/proposal being proposed** in this application must be reported below. If the time commitment or dollar value is not readily ascertainable, reasonable estimates should be provided.

I, PD/PI or other senior/key personnel, certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.

*Signature: _____

Date: _____

Scored Review Criteria (1-9) INVESTIGATORS

- Are the PD(s)/PI(s), collaborators, and other researchers properly trained and well suited to the project?
- Are the collaborators essential for the successful completion of the proposed aims?
- If Early Stage Investigators (≤10 yrs from Ph.D.) or New (No R01) Investigators, or in the early stages of independent careers, do they have appropriate experience and training?
- Do early/new investigators have a tenure track or equivalent position with a firm institutional commitment on space, salary, startup funds etc.
- If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)?
- Does the mentor have the adequate expertise and commitment to mentor the PI?
- Is the Training Plan well developed?

Common Problems with reviewers concerning the investigators

- No demonstration of expertise or publications in the approach section.
- Low productivity, few recent or few primary author papers.
- Needed collaborators not recruited; letters from collaborators missing.
- The collaborator does not complement the research proposed.

Mentors:

- Does the mentor have publications and demonstrated expertise in the field?

- Is the mentor committed to the professional development of the applicant?



Mentor Expectations

- Assist with the outline of an individual development plan (IDP) and ensure that the investigator adheres to the guidelines of the IDP and the INBRE expectations.
- Provide guidance to Developmental project investigators in the logical flow of experiment and hypothesis testing.
- Advise Developmental project investigators on specific deadlines for experimental protocols.
- Advise Developmental project investigators in developing strategies and deadlines for publications.
- Advise Developmental project investigators in the development of specific aims for grant proposals and set specific deadlines for each section of a grant proposal.
- Advise Developmental project investigators with summaries of reviewer critiques from unfunded/unscored applications on strategies for resubmission. Assist with generating the necessary preliminary data to improve resubmissions.
- Serve as an initial reviewer of proposals planned for submission.
- Assist Developmental project investigators in the evaluation of candidate technical staff and research fellows.
- Provide guidance on mentoring of the Developmental project investigator's fellows and students.
- Act as an advocate for the Developmental project investigators with administration and ensure they have "protected time" for research and career development.
- Train Developmental project investigators on the preparation of presentations for national meetings.
- Facilitate access to successful senior investigators through introductions.
- Assist with evaluations from the external evaluator team (EET) and external advisory committee.
- Mentor participation will also be evaluated by the EET, the RC, PC, and PI from the biannual progress reports and questionnaires to the Developmental project investigators.

SPECIFIC AIMS

One Page (not included in 6 or 12 page limit)

- **The single most important section in the grant**
  - It's the master plan for the rest of the proposal
  - You engage or lose the Reviewer on this page
- **It's the most difficult section to write**
  - The logic of each aim must be compelling
  - The answers must be important to the field
- **Write Aims that you are excited about!**

Specific Aims

- Provides an overview of the details - tells what your proposal is about, and how you will get there
  - start with 1 - 2 paragraph general overview
  - then list AIMS, each clearly defined
  - end with a brief statement of what you will learn if successful
- The reader must finish this section convinced that the proposed research is significant and that you have a feasible approach
- The aims should be clearly and concisely stated; many also include sub-aims
- Typically 2 - 4 related aims. Later aims should NOT depend on the success of previous aims

Specific Aims

- Whenever possible – test a hypothesis in the specific aim title
  - You want the Reviewer to know that your work is hypothesis driven
  - Don't make the Reviewer work to figure out what the hypothesis is
- The goal of the aim should be to understand mechanism – even if the experiments are largely descriptive
- 1-2 Specific Aims for a 2-year grant – each aim is a manuscript, or is a significant part of a publication
- The Specific Aims should be detailed but far reaching – the Aims should not be a list of experiments

Specific Aims: Dos

- Write your Aims early – some may fall apart as you design a plan to test them or discuss them with colleagues.
- Try to limit this section to one page – it's a roadmap to the rest of the proposal and it must include the logic behind your aims.
- Don't assume your Reviewer is an expert in your particular area – so write Aims for a non-expert.
- Used to be you couldn't propose OMICs experiments: we love OMICS!

Specific Aims: Don'ts

- Don't state a hypothesis that you cannot actually test with the experiments you are proposing.
- Avoid using phrases like: To correlate… To describe… To develop; these help get your grant pegged as "too descriptive".
- Avoid wishy-washy, passive tense, or flowery language – instead write your aims in active form with strong meaningful verbs.

APPROACH
Significance and Innovation

- 0.5-1 pages **SIGNIFICANCE**
  - Should lead the reader to each question or hypothesis that you're testing in each aim
  - State this explicitly
  - This section must explain why the Study Section should fund your proposal rather than the next one

  What is the "value added" to your field if you're able to do the work?

  INNOVATION

  - Bullets, why is your work different?

Scored Review Criteria 1-9: Significance

- Does the project address an important health problem or a critical barrier to progress in the field?
- If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved?
- How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

- **Common Problems with Significance and Innovation**
  - ✓ Not significant or exciting or new research
  - ✓ Lack of compelling rationale for experiments
  - ✓ Incremental or low impact research
  - ✓ Weak or little biological, biomedical, or behavioral relevance

Scored Review Criteria: 1-9



Innovation:

- Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions?
- Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense?
- Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Criteria for scoring the approach section

Four areas deemed important for enhancing rigor and transparency:

1) **Scientific premise** of the proposed research (Significance)
2) **Scientific rigor**: Rigorous experimental design for robust and unbiased results (Research Strategy)
3) **Consideration of relevant biological variables** (Research Strategy)

4) Authentication of biological resources and chemical resources (Attachment)

1. Scientific Premise

***Premise**: A previous statement or proposition from which another is inferred or follows as a conclusion.*

The scientific premise of the proposed research

In the ***Significance section of your Research Strategy*** - Describe the scientific premise for the proposed project, including consideration of the strengths and weaknesses of published research or preliminary data crucial to the support of your application.

The ***scientific premise*** for an application is the research that is used to form the basis for the proposed research question(s). NIH expects applicants to describe the general strengths and weaknesses of the prior research being cited by the applicant as crucial to support the application. It is expected that this consideration of general strengths and weaknesses could include attention to the rigor of the previous experimental designs, as well as the incorporation of relevant biological variables and authentication of key resources.

Preliminary Studies
(can be in Significance or in Research Strategy)

- In order of Specific Aims
- You don't have to know the outcome of each experiment before the grant is submitted
- You DO have to:
  - Show that you can perform all of the necessary techniques and methods (Letters of Collaboration)
  - You are committed to this area of research and are off and running
  - New techniques are feasible, reliable and yield interpretable data
  - **Show that the preliminary data has scientific rigor**

RESEARCH STRATEGY

Specific Aims are fleshed out with the actual experimental approach

Rationale (1 paragraph) -- logic
Experiments – how? Abbreviated Methods
CONTROLS (positive and negative)
Analysis and Interpretation – what will results mean?
Pitfalls and Alternative Approaches

Your research strategy needs to answer 4 essential questions:

- What do you intend to do?
- Why is the work important?
- What has already been done?
- How are you going to do the work?

Scored Review Criteria: 1-9

Approach

- Are the overall strategy, methodology, and analyses well reasoned and appropriate to accomplish the specific aims of the project?
- Are potential problems, alternative strategies, and benchmarks for success presented?
- If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed?
- How well the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of the literature, preliminary data, and/or logical reasoning.
- How well the hypotheses or objectives, aims, experimental design, methods, and analyses are developed.
- If the project involves Human Subjects Research, are the plans for 1) protection of human subjects from research risks, and 2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?

Approach: page 133: SF424 guidelines:

I.Describe the **overall strategy, methodology**, and analyses to be used to accomplish the specific aims of the project.
Describe the experimental design and methods proposed and how they will achieve robust and unbiased results. Unless addressed separately in Item 15 (Resource Sharing Plan), include how the data will be collected, analyzed, and interpreted as well as any resource sharing plans as appropriate.

II. Discuss **potential problems, alternative strategies**, and benchmarks for success anticipated to achieve the aims.
If the project is in the early stages of development, describe any strategy to establish feasibility, and address the management of any high risk aspects of the proposed work.

Approach: page 133: SF424 guidelines:

III. Explain how relevant biological variables, such as sex, are factored into research designs and analyses for studies in vertebrate animals and humans. For example, strong justification from the scientific literature, preliminary data, or other relevant considerations, must be provided for applications proposing to study only one sex.

IV. If your study(s) involves **human subjects**, you are expected to explain how relevant biological variables are important to the proposed experimental design and analyses.
The sections on the ***Inclusion of Women and Minorities*** and ***Inclusion of Children*** can be used to expand your discussion on inclusion and justify the proposed proportions of individuals (suc h as males and females) in the sample.
Please refer to NOT-OD-15-102 for further consideration of NIH expectations about sex as a biological variable.

2. Scientific Rigor

Rigorous experimental design for robust and unbiased results: Still within the 6 or 12 page limit

o ***Scientific rigor*** is the strict application of the scientific method to ensure robust and unbiased experimental design, methodology, analysis, interpretation and reporting of results. This includes full transparency in reporting experimental details so that others may reproduce and extend the findings.

Criteria for Scientific Rigor:

- Sample size, controls, repetition, statistical power: strength and weakness of experimental design, attention to rigor, the literature cited should be rigorously conducted.
- Address the rigor of the published and preliminary data and in the literature you cite. Is there a strong scientific premise for the research?
- How are you going to address full transparency in experimental details so others can reproduce your results.
- How will you report your results?
- Are your proposed experimental methods robust and **unbiased**?
- Quality of experimental design, statistical analysis, age, weight, sex. randomization, blinding, statistical methods, sample size estimation, appropriate replicates, scientific method, etc.

3. Consideration of relevant biological variables

- ***Biological variables***, such as sex, age, weight, and underlying health conditions, are often critical factors affecting health or disease. In particular, sex is a biological variable that is frequently ignored in animal study designs and analyses, leading to an incomplete understanding of potential sex-based differences in basic biological function, disease processes and treatment response.

- NIH expects that sex as a biological variable will be factored into research designs, analyses, and reporting in vertebrate animal and human studies. Strong justification from the scientific literature, preliminary data or other relevant considerations must be provided for applications proposing to study only one sex.

http://orwh.od.nih.gov

4. Authentication of key biological and/or chemical resources

Key biological and/or chemical resources include, but are not limited to, cell lines, specialty chemicals, antibodies and other biologics. Key biological and/or chemical resources:

1. may differ from laboratory to laboratory or over time
2. may have qualities and/or qualifications that could influence the data
3. are integral to the proposed research
4. are not limited to resources generated with NIH funds

Standard laboratory reagents (e.g. buffers) that are not expected to vary do not need to be included in the plan.

Briefly describe how you plan to authenticate resources. How you will ensure the identity and validity of key biological and/or chemical resources used in the proposed studies.

The quality of resources used to conduct research is critical to the ability to reproduce the results. Each investigator will have to determine which resources used in their research fit these criteria and are therefore key to the proposed research.

10 questions you should answer in each specific aims section of the research strategy

1. What is the question/aim/hypothesis?
2. Why is the question important and necessary to answer?
3. How will your research question if answered overcome hurdles or challenges and impact the field?
4. How are you going to answer this significant and important question; what approaches and why?
5. What could go wrong and what might you do instead and/or in addition?

10 questions you should answer in each specific aims section, contd.



6. How reliable, reproducible, rigorous, and interpretable might the potential data/results be?
7. How might the potential data/results be novel and significant and impact the scientific field?
8. Would anyone care about the results?
9. How would the potential data results answer your question?
10. Depending on potential outcome/results what would you do next?

Common problems with experimental approach

- Lack of clear strong hypothesis or questions
- Too ambitious too much work proposed
- Unfocused or unrelated aims, unclear goals, not integrated
- Limited or narrow aims
- Too much unnecessary experimental details
- Not enough detail on approaches being developed
- Not enough preliminary data to show rationale or significance of project
- Unconvincing preliminary data
- Lack of appropriate controls
- Not directly testing hypothesis
- Correlative or descriptive data
- Experiments not directed towards mechanisms
- No discussion of alternative models or hypotheses
- No discussion of potential pitfalls
- No discussion of data interpretation or future directions

Other Attachments

(Pages 161-162 SF424 Guide)

- **Human Subjects** -Protection of human subjects, Inclusion of women and minorities, Inclusion of children
- **Vertebrate Animals**
- **Select agents research**
- Multiple PI/PD Leadership plan
- Consortium/contractual arrangements
- **Letters of support**
- **Resource sharing plan**
- **Authentication of Key Resources Plan**

Human Subjects Research

https://humansubjects.nih.gov/nih-human-subjects-policies-guidance

View Burden Statement

PHS Inclusion Enrollment Report

This report format should NOT be used for collecting data from study participants.

OMB Number: 0925-0001 and 0925-0002
Expiration Date: 10/31/2018

***Study Title (must be unique):**

* Delayed Onset Study? ☐ Yes ☐ No

If study is not delayed onset, the following selections are required:

Enrollment Type ☐ Planned ☐ Cumulative (Actual)

Using an Existing Dataset or Resource ☐ Yes ☐ No

Enrollment Location ☐ Domestic ☐ Foreign

Clinical Trial ☐ Yes ☐ No **NIH-Defined Phase III Clinical Trial** ☐ Yes ☐ No

Comments:

Racial Categories	Ethnic Categories									
	Not Hispanic or Latino			Hispanic or Latino			Unknown/Not Reported Ethnicity			Total
	Female	Male	Unknown/ Not Reported	Female	Male	Unknown/ Not Reported	Female	Male	Unknown/ Not Reported	
American Indian/ Alaska Native	0	0	0	0	0	0	0	0	0	0
Asian	0	0	0	0	0	0	0	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0	0	0	0	0
Black or African American	0	0	0	0	0	0	0	0	0	0
White	0	0	0	0	0	0	0	0	0	0
More than One Race	0	0	0	0	0	0	0	0	0	0
Unknown or Not Reported	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	0

Report 1 of 1

< Previous Report | Delete Report | Next Report >

To ensure proper performance, please save frequently.

Vertebrate Animals

https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-006.html

Updated VAS Requirements

1. **Description of Procedures**. Provide a concise description of the proposed procedures to be used that involve vertebrate animals in the work outlined in the application or proposal. Identify the species, strains, ages, sex and total number of animals by species to be used in the proposed work.
2. **Justifications.** Provide justification that the species are appropriate for the proposed research.
3. **Minimization of Pain and Distress.** Describe the interventions including analgesia, anesthesia, sedation, palliative care and humane endpoints to minimize discomfort, distress, pain and injury.
4. **Euthanasia.** State whether the method of euthanasia is consistent with the recommendations of the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals. If not, describe the method and provide a scientific justification.

Unscored Review Criteria

Environment

- Will the scientific environment in which the work will be done contribute to the probability of success?

Do not assume! Give details in the Facilities and Resources

- Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed?

include letter of institutional commitment for release time and position: 50% for full projects and 25% for pilot projects

- Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Include strong letters of commitment from mentors and collaborators!

FORMATTING

Text in PDF attachments must follow these minimum requirements:
Don't scan- convert to PDF file!

- Font size: must be 11 points or larger (smaller text in figures, graphs, diagrams and charts is acceptable as long as it is legible when the page is viewed at 100%).
- Type density: must be no more than 15 characters per linear inch (including characters and spaces).
- Line spacing: must be no more than six lines per vertical inch.

Text Color: must be black (color text in figures, graphs, diagrams, charts, tables, footnotes and headings is acceptable as long as it is legible).

- Since some PDF converters may reduce font size, it is important to confirm that the final PDF document complies with the font requirements.
- The following fonts are recommended, although other fonts (both serif and non-serif) are acceptable if they meet the above requirements.

Arial, Garamond, Georgia, Helvetica, Palatino Linotype, Times New Roman, Verdana

- Legibility is of paramount importance. Applications that include PDF attachments that do not conform to the minimum requirements listed above may be withdrawn from consideration.

Other Important Issues

Don't annoy the reviewer!

- Page requirements: 6 (pilot) or 12 (full) pages
- Font size and line spacing
- SPACING OF TEXT SECTIONS
- Embed figures into the text. Include a brief, clear legend.
- Figure must be absolutely clear/visible to the Reviewer.
- Learn how to use MS Word
- Spelling and grammar – ZERO TOLERANCE for sloppy mistakes.

Budget

Program Director/Principal Investigator (Last, First, Middle):

DETAILED BUDGET FOR INITIAL BUDGET PERIOD
DIRECT COSTS ONLY

FROM | THROUGH

List PERSONNEL *(Applicant organization only)*
Use Cal, Acad, or Summer to Enter Months Devoted to Project
Enter Dollar Amounts Requested *(omit cents)* for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summer Mnths	INST.BASE SALARY	SALARY REQUESTED	FRINGE BENEFITS	TOTAL
	PD/PI							
SUBTOTALS →								

CONSULTANT COSTS	
EQUIPMENT *(Itemize)*	
SUPPLIES *(Itemize by category)*	
TRAVEL	
INPATIENT CARE COSTS	
OUTPATIENT CARE COSTS	
ALTERATIONS AND RENOVATIONS *(Itemize by category)*	
OTHER EXPENSES *(Itemize by category)*	

CONSORTIUM/CONTRACTUAL COSTS	DIRECT COSTS	
SUBTOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD *(Item 7a, Face Page)*		$
CONSORTIUM/CONTRACTUAL COSTS	FACILITIES AND ADMINISTRATIVE COSTS	
TOTAL DIRECT COSTS FOR INITIAL BUDGET PERIOD		$

Program Director/Principal Investigator (Last, First, Middle):

BUDGET FOR ENTIRE PROPOSED PROJECT PERIOD
DIRECT COSTS ONLY

BUDGET CATEGORY TOTALS	INITIAL BUDGET PERIOD *(from Form Page 4)*	2nd ADDITIONAL YEAR OF SUPPORT REQUESTED	3rd ADDITIONAL YEAR OF SUPPORT REQUESTED	4th ADDITIONAL YEAR OF SUPPORT REQUESTED	5th ADDITIONAL YEAR OF SUPPORT REQUESTED
PERSONNEL: *Salary and fringe benefits. Applicant organization only.*					
CONSULTANT COSTS					
EQUIPMENT					
SUPPLIES					
TRAVEL					
INPATIENT CARE COSTS					
OUTPATIENT CARE COSTS					
ALTERATIONS AND RENOVATIONS					
OTHER EXPENSES					
DIRECT CONSORTIUM/ CONTRACTUAL COSTS					
SUBTOTAL DIRECT COSTS *(Sum = Item 8a, Face Page)*					
F&A CONSORTIUM/ CONTRACTUAL COSTS					
TOTAL DIRECT COSTS					

TOTAL DIRECT COSTS FOR ENTIRE PROPOSED PROJECT PERIOD $

JUSTIFICATION. Follow the budget justification instructions exactly. Use continuation pages as needed.

Full: $250,000
Pilot: $75,000

Program Director/Principal Investigator (Last, First, Middle):

CHECKLIST

TYPE OF APPLICATION *(Check all that apply.)*

☐ NEW application. *(This application is being submitted to the PHS for the first time.)*

☐ RESUBMISSION of application number: _____
(This application replaces a prior unfunded version of a new, renewal, or revision application.)

☐ RENEWAL of grant number: _____
(This application is to extend a funded grant beyond its current project period.)

☐ REVISION to grant number: _____
(This application is for additional funds to supplement a currently funded grant.)

☐ CHANGE of program director/principal investigator.

Name of former program director/principal investigator: _____

☐ CHANGE of Grantee Institution. Name of former institution: _____

☐ FOREIGN application ☐ Domestic Grant with foreign involvement List Country(ies) Involved: _____

INVENTIONS AND PATENTS *(Renewal appl. only)* ☐ No ☐ Yes

If "Yes," ☐ Previously reported ☐ Not previously reported

1. PROGRAM INCOME ***(See instructions.)***
All applications must indicate whether program income is anticipated during the period(s) for which grant support is request. If program income is anticipated, use the format below to reflect the amount and source(s).

Budget Period	Anticipated Amount	Source(s)

2. ASSURANCES/CERTIFICATIONS ***(See instructions.)***
In signing the application Face Page, the authorized organizational representative agrees to comply with the policies, assurances and/or certifications listed in the application instructions when applicable. Descriptions of individual assurances/certifications are provided in the NIH Grants Policy Statement, Section 4: Public Policy Requirements, Objectives and Other Appropriation Mandates. If unable to certify compliance, where applicable, provide an explanation and place it after this page.

3. FACILITIES AND ADMINSTRATIVE COSTS (F&A)/ INDIRECT COSTS. See specific instructions.

☐ HHS Agreement dated: _____ ☐ No Facilities And Administrative Costs Requested.

☐ HHS Agreement being negotiated with _____ Regional Office.

☐ No HHS Agreement, but rate established with _____ Date _____

CALCULATION* *(The entire grant application, including the Checklist, will be reproduced and provided to peer reviewers as confidential information.)*

a. Initial budget period: Amount of base $ _____ x Rate applied _____ % = F&A costs $ _____

b. 02 year Amount of base $ _____ x Rate applied _____ % = F&A costs $ _____

c. 03 year Amount of base $ _____ x Rate applied _____ % = F&A costs $ _____

d. 04 year Amount of base $ _____ x Rate applied _____ % = F&A costs $ _____

e. 05 year Amount of base $ _____ x Rate applied _____ % = F&A costs $ _____

Enter Rate above as a decimal (e.g., 0.25 for 25%, 0.495 for 49.5%) TOTAL F&A Costs $ _____

*Check appropriate box(es):

☐ Salary and wages base ☐ Modified total direct cost base ☐ Other base *(Explain)*

☐ Off-site, other special rate, or more than one rate involved *(Explain)*

Explanation *(Attach separate sheet, if necessary.):*

Please, include a **checklist** at the end of your application.

Your institution must have a **FHA agreement** with the Department of Human Health.

The indirect costs (FHA costs) have to be included in the proposal.

Your INBRE DRPP Award

- Please, note that prior to starting your project, you are required to contact the PR-INBRE Bioinformatics Resource Core at **help@hpcf.upr.edu**, to receive their advice and guidance in designing and analyzing your experiments.

- Please, include this award in your biosketch as a subproject from the NIGMS/**INBRE award P20 GM103475-19**, Project Title: “Advancing Competitive Biomedical Research in Puerto Rico”, PI: Jose Rodriguez-Medina, Ph.D.

- You are the **PI of a subproject** under this award, and should list your name and title of sub project following this information.

- **Any publications resulting from the use of these funds** should acknowledge the PR-INBRE Program with the following statements: "Research reported in this publication was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20 GM103475-19. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

DRPP Activities

Welcome to the PRINBRE Family!

- Monthly peer-review meetings.
- Review of grant applications and manuscripts.
- Annual PRINBRE retreat and EAC meeting.
- Workshops, mentoring
- Annual progress reports